Dulcolax is an international over-the-counter (OTC) constipation-relief brand, primarily recognized for its products containing bisacodyl, a stimulant laxative used to treat occasional constipation. The brand is currently owned by Opella, a global self-care company that manages a portfolio of OTC and consumer-health brands. Opella became an independent entity in 2025 following its separation from Sanofi’s consumer-health division.

The Dulcolax product portfolio varies significantly across different markets. Consequently, formulations sold under the Dulcolax name in one country may differ in ingredients or indications from those available in others, such as the United States, the United Kingdom, or Indonesia.

The history of Dulcolax is intrinsically linked to bisacodyl, the active ingredient that established the brand’s position in the laxative market.

According to brand records, bisacodyl was invented in 1948 in the laboratories of Dr. Karl Thomae. It was developed as an oral laxative designed to act directly within the gastrointestinal tract. A U.S. patent for bisacodyl was granted in 1956. 1

A significant milestone occurred in 1952, when enteric-coated bisacodyl tablets were launched in Germany under the Dulcolax name. The brand subsequently expanded internationally, including a launch in Canada in 1958. Suppository formulations were introduced during the early development phase of the brand.

Simplified timeline

• 1948 — Bisacodyl is invented at Dr. Karl Thomae laboratories.
• 1952 — Bisacodyl enteric-coated tablets launch in Germany under Dulcolax.
• 1953 — Dulcolax bisacodyl suppositories are launched.
• 1956 — U.S. patent for bisacodyl is granted.
• 1958 — Dulcolax expands into additional markets, including Canada.
• 2002 — Dulcolax suppositories and stool-softener products expand in the U.S.
• 2019 — Dulcolax Liquid launches in the U.S.
• 2020 — Dulcolax Soft Chews launch in the U.S.
• 2024–2025 — The brand moves into the newly independent Opella organization.

With roots dating back approximately seven decades, Dulcolax remains one of the established international brands in the constipation-relief category.

The primary function of Dulcolax is to relieve constipation, particularly in cases where individuals experience difficulty passing stool.

In many markets, including Indonesia, the standard Dulcolax tablet contains 5 mg of bisacodyl. This enteric-coated tablet is designed to withstand the acidic environment of the stomach, releasing its active ingredient further down the digestive tract. Product information indicates that bisacodyl stimulates movement in the large intestine, facilitating bowel movements.

The physiological process can be summarized as follows:

Dulcolax → reaches the intestine → bisacodyl acts on the bowel → intestinal movement increases → bowel movement becomes easier.

As a stimulant laxative, abdominal cramping or the urge to defecate may occur. Manufacturer information notes that mild cramping is a normal effect associated with the mechanism of action.

Bisacodyl

Bisacodyl is the ingredient most closely associated with the Dulcolax brand. It belongs to the stimulant laxative class. Unlike bulk-forming agents, bisacodyl promotes intestinal activity to facilitate evacuation.

The standard Dulcolax tablet utilizes a gastro-resistant or enteric coating, allowing it to pass through the stomach and small intestine before releasing the active ingredient. Onset of action typically occurs within 6–12 hours, which is why the tablet is commonly taken at night to induce a bowel movement the following morning.

It is important to note that Dulcolax is a brand family rather than a single chemical formulation. Depending on the market, the range may include other active ingredients. For example, the UK portfolio includes:

• Bisacodyl tablets
• Bisacodyl suppositories
• Sodium picosulfate liquid
• Docusate sodium in DulcoEase capsules

Therefore, while “Dulcolax” often refers to bisacodyl products, the global brand encompasses various formulations.

1. Dulcolax Tablets

This is the format most commonly associated with the brand. Standard tablets contain bisacodyl 5 mg and feature an enteric coating. The onset of action is approximately 6–12 hours.

The intended usage pattern is: Take at night → effect during the night/morning → bowel movement the next day. Specific age recommendations and dosing instructions vary by local labeling.

2. Dulcolax Suppositories

Dulcolax is also available as a rectal suppository. These formulations contain bisacodyl and are designed to act locally after administration. The advertised onset of action is from approximately 10 minutes, making this form substantially faster-acting than the oral tablet.

3. Other Products

The international Dulcolax portfolio extends beyond traditional tablets and suppositories. In some markets, such as the United States, the range includes liquid gels, soft chews, powder, and daily gut-support products. The UK market offers liquids and DulcoEase capsules. This variety reflects a strategy of providing a family of constipation and digestive-health solutions rather than a single product type.

Dulcolax holds a recognizable position in the Indonesian constipation-relief market. The local brand website describes Dulcolax as a non-prescription laxative available in more than 90 countries. The Indonesian portfolio emphasizes three distinct consumer propositions:

“Bekerja dalam semalam” (Works overnight)

The traditional Dulcolax tablet uses bisacodyl and is positioned around a 6–12 hour onset.

“Bekerja nyaman” (Comfortable relief)

The portfolio includes Dulcolactol, which contains lactulose. It is positioned as a stool-softening product, distinct from the stimulant-laxative formulation of the bisacodyl tablets.

“Bekerja cepat” (Fast relief)

Dulcolax suppositories are positioned for rapid action, with effects beginning from approximately 10 minutes.

This structure allows consumers to choose based on their specific needs: Overnight → Comfortable → Fast.

Historically, Dulcolax has positioned itself around predictability, effectiveness, and convenience in constipation relief.

Current global branding focuses on helping consumers “feel good on the inside” to resume their daily activities. The brand’s mission involves developing consumer- and science-based solutions for gut function. 2 From a marketing perspective, Dulcolax sells the outcome—relief from constipation—rather than just the pharmaceutical ingredient.

constipation → relief → return to normal daily activity.

Historical Corporate Relationship

For many years, Dulcolax was associated with Boehringer Ingelheim and later with Sanofi’s consumer-health business, depending on the market and time period.

Sanofi reorganized its consumer-health activities under Opella. In 2024, Sanofi announced an agreement involving a controlling stake in Opella held by private-equity firm Clayton, Dubilier & Rice (CD&R), while Sanofi remained a significant shareholder.

Current Ownership

As of 2026, Dulcolax is an Opella brand. Opella operates a portfolio of approximately 100 consumer-health brands serving more than half a billion consumers worldwide. 3 Opella officially launched as an independent company in 2025.

The simplified corporate lineage is:
Dr. Karl Thomae / early bisacodyl development → Dulcolax international brand → Boehringer Ingelheim → Sanofi Consumer Healthcare → Opella

Dulcolax is an international brand available in more than 90 countries. Naming conventions may vary slightly by region, such as Dulcolax versus DulcoLax. Related brands like DulcoEase may also form part of local portfolios.

Product compositions and age indications are not globally identical, requiring consumers to check local packaging for specific details.

It is useful to distinguish Dulcolax from other categories of constipation treatment:

Traditional Dulcolax bisacodyl products belong to the stimulant-laxative category. The appropriate treatment depends on the type and duration of constipation, patient age, other medications, underlying conditions, and local medical guidance.

From a business perspective, Dulcolax has successfully transformed a common health issue—constipation—into a highly recognizable consumer brand. Its equity is built on several pillars:

1. Recognition: Decades of association with constipation relief.
2. Predictability: The overnight action of the traditional tablet provides clear expectations.
3. Multiple Formats: Tablets, suppositories, and other forms address different preferences.
4. Scientific Heritage: Linked to the development of bisacodyl.
5. International Scale: Expanded from European origins to a multinational presence.

Dulcolax is a brand within Opella, not the company name itself. Opella’s broader portfolio includes brands such as Allegra, Buscopan, Doliprane, Enterogermina, Essentiale, and Mucosolvan. Opella describes itself as a global self-care company focused on OTC medicines and vitamins, minerals, and supplements.

Within Opella, Dulcolax occupies a specific niche:
Opella → Digestive health → Dulcolax → Constipation relief

Other Opella brands address allergies, pain, respiratory conditions, and other consumer-health needs. Contemporary branding positions Dulcolax as part of a broader gut-health and self-care proposition, aligning with Opella’s mission to make self-care simpler and more accessible. 3

1. Dulcolax® Ahlinya Mengatasi Susah BAB
2. Constipation Relief Treatment
3. Opella